Zoetis (NYSE: ZTS) reported Q2 EPS of $0.77, $0.07 better than the analyst estimate of $0.70. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.38 billion.

“We continue to perform well through the first half of 2018 primarily based on the performance of new parasiticides and vaccines, our dermatology portfolio, as well as contributions from the rest of our in-line portfolio,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis. “Our acquisition of Abaxis this week also demonstrates our ongoing commitment to strategic portfolio expansions and value creation for our customers and shareholders. We are updating our guidance to reflect the addition of Abaxis and changes in foreign exchange, and we are confident in our ability to meet these goals for the full year.”

GUIDANCE:

Zoetis sees Q3 2018 EPS of $3.00-$3.10, versus the consensus of $3.06. Zoetis sees Q3 2018 revenue of $5.7-5.8 billion, versus the consensus of $5.74 billion.

For earnings history and earnings-related data on Zoetis (ZTS) click here.